Ning Kang

Ning Kang

Auto-generated profile, based on publicly available information

Ning Kang

Department of Experimental Therapeutics, BC Cancer, Vancouver, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Epigenomics
Verified
Journal Article
Open access
NKNing Kang
Ning Kang
MEMark Eccleston
Mark Eccleston
PCPier-Luc Clermont
Pier-Luc Clermont
MLMaryam Latarani
Maryam Latarani
DMDavid Male
David Male
FCFrancesco Crea
Francesco Crea
Immunotherapies are revolutionizing the clinical management of a wide range of cancers. However, intrinsic or acquired unresponsiveness to immunotherapies does occur due to the dynamic cancer immun...

14 July 2023 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
NKNing Kang
Ning Kang
HXHui Xue
Hui Xue
YLYen-Yi Lin
Yen-Yi Lin
XDXin Dong
Xin Dong
ACAdam Classen
Adam Classen
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang
Androgen deprivation therapy (ADT) is the standard care for advanced prostate cancer (PCa) patients. Unfortunately, although tumors respond well initially, they enter dormancy and eventually progress to fatal/incurable castration-resistant prostate cancer (CRPC). B7-H3 is a promising new target for PCa immunotherapy. CD276 (B7-H3) gene has a presumptive androgen receptor (AR) binding site, suggesting potential AR regulation. However, the relationship between B7-H3 and AR is controversial. Meanwhile, the expression pattern of B7-H3 following ADT and during CRPC progression is largely unknown, but critically important for identifying patients and determining the optimal timing of B7-H3 targeting immunotherapy. In this study, we performed a longitudinal study using our unique PCa patient-derived xenograft (PDX) models and assessed B7-H3 expression during post-ADT disease progression. We further validated our findings at the clinical level in PCa patient samples. We found that B7-H3 expression was negatively regulated by AR during the early phase of ADT treatment, but positively associated with PCa proliferation during the remainder of disease progression. Our findings suggest its use as a biomarker for diagnosis, prognosis, and ADT treatment response, and the potential of combining ADT and B7-H3 targeting immunotherapy for hormone-naïve PCa treatment to prevent fatal CRPC relapse.

7 January 2025 in Molecular Cancer Research
Verified
Journal Article
Closed access
NKNing Kang
Ning Kang
HXHui Xue
Hui Xue
NWNelson Wong
Nelson Wong
YLYen-Yi Lin
Yen-Yi Lin
ACAdam Classen
Adam Classen
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang
Prostate cancer is mainly managed with androgen deprivation therapy (ADT), but this often leads to a dormant state and subsequent relapse as lethal castration-resistant prostate cancer (CRPC). Using our unique prostate cancer patient-derived xenograft dormancy models, we investigated this critical dormant phase and discovered a selective increase in B7-H4 expression during the dormancy period following mouse host castration. This finding is supported by observations in clinical specimens of patients with prostate cancer treated with ADT. Differential expression analyses revealed the enrichment of extracellular matrix (ECM)–cell interaction pathways in B7-H4–positive cells. Functional assays demonstrated a crucial role of B7-H4 in maintaining dormancy within the ECM niche. Specifically, B7-H4 expression in LNCaP cells reduced proliferation within the dormant ECM in vitro and significantly delayed relapse in castrated hosts in vivo. These results shed light on the dynamic regulation of B7-H4 during prostate cancer dormancy and underscore its potential as a therapeutic target for preventing CRPC relapse. Implications: Our study identified membranous B7-H4 expression during ADT-induced dormancy, highlighting its potential as a therapeutic target for managing dormant prostate cancer and preventing fatal CRPC relapse.

1 April 2025 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
NWNelson Wong
Nelson Wong
NKNing Kang
Ning Kang
CDClaire Dourieu
Claire Dourieu
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang
Editorial Commentary Exploiting pre-dormancy tumor immune microenvironment induced by androgen deprivation in prostate cancer Nelson K. Y. Wong, Ning Kang, Claire Dourieu, Yuzhuo Wang

17 June 2026
Verified
Other
Open access
NKNing Kang
Ning Kang
HXHui Xue
Hui Xue
NWNelson Wong
Nelson Wong
YLYen-Yi Lin
Yen-Yi Lin
ACAdam Classen
Adam Classen
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang
Fig. S2. VTCN1 (mouse B7-H4) expression enriched in post-castration prostate tissue in a normal mouse prostate tissue castration model.

17 June 2026
Verified
Other
Open access
NKNing Kang
Ning Kang
HXHui Xue
Hui Xue
NWNelson Wong
Nelson Wong
YLYen-Yi Lin
Yen-Yi Lin
ACAdam Classen
Adam Classen
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang
Fig. S1. scRNA-seq analysis of human prostate cancer cells from the LTL331 PDX model showing VTCN1 expression across all 17 clusters.